Should prostate cancer genomic classifiers, such as Decipher, be used in all high risk post-prostatectomy patients to risk stratify patients to adjvant RT vs PSA observation and possible salvage RT?
The optimal timing of post-prostatectomy RT in high-risk patients is debatable and currently the question of prospective randomized trials; however, given the recent JCO article by Den et al (3/10/15) regarding the benefit of the genomic classifier Decipher, should this be the standard method of determining whether adjuvant RT vs. salvage RT should be utilized in this high-risk cohort?
Answer from: Radiation Oncologist at Academic Institution
I think that the data are hypothesis generating and can assist in physician decision making. Additional analysis from other independent cohorts substantiate the findings from the JCO paper whose publications will be forthcoming. It is important to discuss the findings, including the limitations, w...
Sign in or Register to read more